KEAP1 and cancer: A comprehensive genomic analysis of squamous cell lung cancers revealed that 34% of these cancers harboured somatic mutations in NFE2L2 (19%), KEAP1 (12%) or CUL3 (7%), resulting in the downregulation of NRF2 repressors and activation of NRF2 [202].